Cambridge, UK – SolasCure, a biotechnology research company that leverages biomimicry and evidence-based medicine to develop fit-for-purpose, efficacious wound care products significantly improve the health and well-being of patients, announced it has secured $13.4 million in a Series B funding round led by Wealth Club with participation from Seneca Partners and BRAIN Biotech AG. The funds will accelerate product development and enable the company to expand its reach into new markets.

“We are thrilled to have received this investment from such high-profile investors who share our vision in creating innovative products that improve patient outcomes," said Sam Bakri, Founder of SolasCure. "This investment allows us to continue building on our success and progress towards bringing more life-changing products to market.”

Founded by Sam Bakri, SolasCure is a Cambridge-based biotechnology research company focused on developing advanced wound care products using biomimicry and evidence-based medicine principles. The company’s flagship product is an advanced wound dressing designed to reduce healing time while providing superior protection against microbial contamination compared to traditional dressings. Additionally, the dressing can be applied quickly resulting in less disruption for patients during treatment sessions.